Ramucirumab reportedly activates tumor immunity and its antiangiogenic activity [22], and FTD/TPI reportedly eliminates TAM2, resulting in cytotoxic CD8+ T-cell infiltration and activation [23]. Here, CD8A is linked to neoplasm.